Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model

PURPOSE: Randomized trials established the superiority of ibrutinib-based therapy over chemoimmunotherapy in chronic lymphocytic leukemia. Durability of progression-free survival (PFS) with ibrutinib can vary by patient subgroup. Clinical tools for prognostication and risk-stratification are needed....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Ahn, Inhye E., Tian, Xin, Ipe, David, Cheng, Mei, Albitar, Maher, Tsao, L. Claire, Zhang, Lei, Ma, Wanlong, Herman, Sarah E. M., Gaglione, Erika M., Soto, Susan, Dean, James P., Wiestner, Adrian
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2021
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8189626/
https://ncbi.nlm.nih.gov/pubmed/33026937
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00979
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi